Skip to main content

lisinopril

ADVERTISEMENT
Identification
Molecular formula
C21H31N3O5
CAS number
83915-83-7
IUPAC name
7-[(1-ethoxycarbonyl-3-phenyl-propyl)amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
State
State

At room temperature, lisinopril is in a solid state, appearing as a crystalline powder.

Melting point (Celsius)
162.00
Melting point (Kelvin)
435.15
Boiling point (Celsius)
196.80
Boiling point (Kelvin)
469.95
General information
Molecular weight
441.52g/mol
Molar mass
441.5230g/mol
Density
1.4507g/cm3
Appearence

The compound appears as a white or almost white crystalline powder.

Comment on solubility

Solubility of 7-[(1-ethoxycarbonyl-3-phenyl-propyl)amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid

The solubility of the compound C21H31N3O5 is an interesting subject, as it encompasses various factors that influence its behavior in different solvents. Here are some key points to consider:

  • Polar vs. Non-Polar Solvents: Generally, compounds with polar functional groups, like carboxylic acids, exhibit higher solubility in polar solvents such as water. In contrast, non-polar solvents may not dissolve such compounds well.
  • pH Dependency: The solubility of acidic compounds can significantly increase in alkaline solutions due to deprotonation, facilitating better interaction with solvent molecules.
  • Hydrogen Bonding: If the compound can form hydrogen bonds, its solubility is often enhanced in polar solvents. This process allows the molecules to interact favorably with solvent molecules.
  • Temperature Influence: Increasing temperature can enhance the solubility of many compounds. However, this is not universal, as some compounds may exhibit decreased solubility at higher temperatures due to changes in crystalline structure.
  • Impurities and Additives: The presence of other substances can either increase or decrease solubility — such as surfactants, which can aid in dissolving otherwise poorly soluble compounds.

In summary, the solubility of C21H31N3O5 is influenced by its chemical structure, the nature of the solvent, and external conditions. Understanding these interactions is crucial for effective application in various fields, such as pharmaceuticals.

Interesting facts

Interesting Facts about 7-[(1-ethoxycarbonyl-3-phenyl-propyl)amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid

This compound represents a fascinating area of study due to its structural complexity and potential applications in medicinal chemistry. Here are some intriguing aspects:

  • Multifunctional Structure: The compound features multiple functional groups, including carboxylic acids and amines, making it an excellent candidate for various biological activities.
  • Potential Pharmacological Applications: Compounds with similar structures are often investigated for their therapeutic properties, especially in treating neurological disorders. Their ability to cross the blood-brain barrier is of significant interest.
  • Sp3 Hybridization: The presence of potential chiral centers in the structure allows for the exploration of stereochemistry, which can lead to different biological activities depending on their orientation.

The unique octahydropyridazino scaffold in this compound is noteworthy. It is considered a scaffold which can enhance the binding affinity towards various biological targets. Additionally, the combination of the phenyl and ethoxycarbonyl functionalities can influence the lipophilicity and thus the pharmacokinetic properties of the entire molecule. Scientists often emphasize that understanding the interplay between structure and activity is key in drug discovery.

Overall, this compound exemplifies the complexity of molecular design in creating potential pharmaceuticals. As stated by a prominent chemist, “The beauty of chemistry lies not just in the molecules we create but in the vast potential they hold.”

Synonyms
104013-57-2
7-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
SCHEMBL10368731
DTXSID00274385
DTXSID90861107
NCGC00389445-01
DB-057104
NS00100931
9-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
9a[(1aEthoxya1aoxoa4aphenylbutana2ayl)amino]a10a oxoaoctahydroa1Hapyridazino[1,2aa][1,2]diazepinea1a carboxylic acid